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Résumé en
anglais
BACKGROUND: The Enhanced Liver Fibrosis (ELF) score combining serum
hyaluronan, N-terminal peptide of type III procollagen and tissue inhibitor of
metalloproteinase-1, was reported as relevant in predicting liver fibrosis in chronic
liver disease and proposed as an alternative to liver biopsy.
METHODS: We evaluated the ELF score in a cohort of chronic hepatitis C (CHC)
patients included in a multicenter prospective study (ANRS HC EP 23 Fibrostar)
using commercial reagents, different from those developed by the manufacturer of
the Siemens ELF™ test.
RESULTS: In 512 CHC, the ELF score, using ROC curves, showed good predictive
performances for severe fibrosis [AUROC=0.82; 95% confidence interval (CI)
0.78-0.86]and for cirrhosis (AUROC=0.85; 95% CI 0.81-0.90), but slightly lower for
significant fibrosis (AUROC=0.78; 95% CI 0.74-0.82). The Obuchowski measure
(0.81) showed that the ELF score globally performed as a marker of liver fibrosis.
The ELF score predicted significant fibrosis (cut-off=9.0) with a sensitivity of 0.86,
a specificity of 0.62, a positive predictive value (PPV) of 0.80 and a negative
predictive value (NPV) of 0.70. For extensive fibrosis (cut-off=9.33), sensitivity was
0.90, specificity was 0.63, PPV was 0.73 and NPV was 0.85. For cirrhosis (cut-
off=9.35), sensitivity was 0.83, specificity was 0.75, PPV was 0.44 and NPV was
0.95.
CONCLUSIONS: This study confirms the ELF score performance as an index to
predict liver fibrosis or cirrhosis in CHC. The ELF test, using validated reagents,
could be added to the health authorities approved non-invasive tests in assessing
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